Form 424B3 LENZ Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
LENZ Therapeutics Inc (LENZ) PT Lowered to $32 at Citi
August 15, 2024 4:58 AM EDTCiti analyst Yigal Nochomovitz lowered the price target on LENZ Therapeutics Inc (NASDAQ: LENZ) to $32.00 (from $34.00) while maintaining a Buy rating.
The analyst comments "LENZ continues to execute very effectively on pre-commercialization plans for LNZ100 in presbyopia. While there was not... More
